Alfred Wang

Alfred Wang has a strong background in the biotechnology and pharmaceutical industry. Alfred started their career as a Research Intern at Roche Bioscience in 1998 and later worked as a Research Intern at Genentech in 1999. In 2001, Alfred joined Ingenuity Systems as a Consulting Scientist. Alfred then transitioned to Strategic Decisions Group (SDG) in 2006, where they worked as an Associate Consultant for a brief period. Alfred then moved to IMS Consulting Group the same year and served as a Consultant until 2009. During their time at IMS, they advanced to the role of Senior Consultant, specializing in Strategy & Portfolio Analysis.

In 2013, Alfred joined Gilead Sciences as a Senior Manager, focusing on Pipeline Marketing Sciences and Commercial Planning. Alfred worked at Gilead Sciences until 2016.

In 2016, Alfred joined Exelixis as a Senior Director in Market Planning. After two years, they advanced to the role of Executive Director, responsible for Commercial Strategy & Planning, and stayed with the company until 2022.

Following their tenure at Exelixis, Alfred joined Chinook Therapeutics, Inc. as an Executive Director in Marketing and New Product Planning. Alfred worked at Chinook Therapeutics for two years before joining Structure Therapeutics in 2024.

Currently, Alfred holds the position of Vice President, leading Commercial Strategy & New Product Planning at Structure Therapeutics.

Alfred Wang received their Bachelor of Science degree in Biology from Caltech in 1999. Alfred then pursued their PhD in Molecular Pharmacology at Stanford University School of Medicine, graduating in 2006.